CCS Medical, RoTech Healthcare Inc. and Reliant Pharmacy have been warned by the FDA to stop mas-producing unapproved inhalation drugs. While the targeted companies argue that they are engaging in the practice of traditional pharmacy compounding, the FDA disagrees. Traditional pharmacy compounding is usually done to prepare a unique medicine for a patient when an FDA-approved drug doesn’t meet their special needs. Conditions like asthma, bronchitis and emphysema are treated with inhalation drugs, and there are numerous available FDA-approved drugs for these diseases. The FDA urges patients to use FDA-approved inhalation drugs, as there may be problems with the safety and effectiveness of compounded inhalation drugs.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.